You are here
SARS-CoV-2 Vaccine Clinical Trials Using ACTIV-Informed Harmonized Protocols
ACTIV advised on the protocol designs and endpoints to ensure a harmonized approach across multiple vaccine efficacy trials. The protocol enables analyses of correlates of protection across several vaccine trials being implemented under Operation Warp Speed and activated at sites that are part of the NIH COVID-19 Prevention Network.
As vaccine clinical trials using these harmonized protocols are launched, NIH will list those studies this page.
SARS-CoV-2 Vaccine Clinical Trials Using
Harmonized Protocols Informed by ACTIV
|Agent||Trial Phase||Description||More Information|
An investigational vaccine to evaluate prevention of symptomatic COVID-19 in adults. The vaccine was co-developed by Moderna, Inc., and NIAID.
This page last reviewed on August 4, 2020